Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
U.S. News & World Report7d
Novavax Sees Royalties, Reduced Expenses on COVID Vaccines From Sanofi Partnership
Novavax in May had signed a deal worth at least ... were placed on the U.S. Food and Drug Administration's ability to review products. Its net loss was $81 million for the quarter ended December ...
Yahoo Finance15d
Novavax to Report Q4 Earnings: Here's What You Can Expect
Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...